Interstitial Lung Disease Pipeline Assessment, 2022: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies Involved

August 25 14:30 2022
Interstitial Lung Disease Pipeline Assessment, 2022: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies Involved
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 120+ key pharma and biotech companies are working on 120+ pipeline drugs in the Interstitial Lung Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

“Interstitial Lung Disease Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market. 

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

DelveInsight’s Report covers around 120+ products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 Interstitial Lung Disease Pipeline Analysis

Interstitial Lung Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Interstitial Lung Disease Treatment.

  • Interstitial Lung Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Interstitial Lung Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report –

Interstitial Lung Disease Therapeutics Landscape

There are approx. 120+ key companies which are developing therapies for Interstitial Lung Disease. Currently, Pfizer has its Interstitial Lung Disease drug candidates in the most advanced stage of clinical development. 

Some of the key companies in the Interstitial Lung Disease Therapeutics Market include:

Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and Others.


Interstitial Lung Disease Emerging Drugs Covered in the report include:

DWN12088: Daewoong Pharmaceutical  

LYT-100: PureTech

BMS-986278: Bristol-Myers Squibb

Further product details are provided in the report. Download the sample pages to get more information:


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Interstitial Lung Disease Current Treatment Patterns

4. Interstitial Lung Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Interstitial Lung Disease Late Stage Products (Phase-III)

7. Interstitial Lung Disease Mid-Stage Products (Phase-II)

8. Interstitial Lung Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Interstitial Lung Disease Discontinued Products

13. Interstitial Lung Disease Product Profiles

14. Key Companies in the Interstitial Lung Disease Market

15. Key Products in the Interstitial Lung Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Interstitial Lung Disease Unmet Needs

18. Interstitial Lung Disease Future Perspectives

19. Interstitial Lung Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Papilloma Market
“Papilloma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Papilloma Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States